Following this activity, participants should be able to:

Sequencing Therapy for Advanced Non-Small Cell Lung Cancer

• Discuss sequencing of systemic therapy for patients with metastatic NSCLC and ALK gene rearrangements.
• Describe sequencing of systemic therapy for patients with metastatic NSCLC and sensitizing EGFR mutations.
• Identify the subsequent therapy regimens for patients with wild-type NSCLC.
• Select the most appropriate subsequent therapy regimens for patients with advanced NSCLC who have progressed after first-line systemic therapy.
• Discuss sequencing of systemic therapy for patients with metastatic NSCLC and ROS1 gene rearrangements.
• Describe the different biomarkers for which effective targeted therapy is available for patients with metastatic NSCLC.

Immunotherapies in Lung Cancer

• Identify the new recommended immunotherapy regimens for patients with SCLC and NSCLC.
• Evaluate the risks and benefits of using immune-checkpoint inhibitor therapy.
• Educate health care providers about adverse events that may occur with immunotherapy and appropriate management.
• Describe the challenges with diagnosing pneumonitis.
• Summarize the role of biomarker testing to assist with selecting the most appropriate immunotherapeutic agents for patients with metastatic NSCLC.

Managing Toxicities of Newer Agents

• Describe the spectrum of immune-related adverse events that may occur with immune-checkpoint inhibitor therapy.
• Educate patients and their caregivers about symptoms suggestive of immune-related adverse events.
• Manage immune-related adverse events associated with immune-checkpoint inhibitor therapy.
• Monitor for and manage patients who have adverse events associated with ALK inhibitors.

What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer

• Identify the appropriate use of liquid biopsy and tissue biopsy in assessing for biomarkers in patients with metastatic NSCLC.
• Describe the recommended molecular testing for patients with NSCLC and sensitizing EGFR mutations and T790M.
• Summarize the currently known mechanisms for primary and secondary resistance to erlotinib, gefitinib, and afatinib.

New Strategies to Improve the Accuracy of Lung Cancer Screening

• Discuss the risk assessment process used to determine whether patients are candidates for lung cancer screening.
• Evaluate and follow-up the findings of different types of nodules that may be detected on low-dose computed tomography.
• Identify when to recommend further screening, biopsy, surgical excision of nodules based on recommendations in the NCCN Guidelines^® for Lung Cancer Screening.
• Appropriately counsel patients about the risks and benefits of lung cancer screening.